<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18835" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Captopril</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marte</surname>
            <given-names>Francheska</given-names>
          </name>
          <aff>St. John's University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sankar</surname>
            <given-names>Parvathy</given-names>
          </name>
          <aff>Michigan State University College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cassagnol</surname>
            <given-names>Manouchkathe</given-names>
          </name>
          <aff>St. John's University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Francheska Marte declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Parvathy Sankar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18835.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Captopril is an FDA-approved medication that plays a pivotal role in managing hypertension, left ventricular dysfunction post-myocardial infarction, and diabetic nephropathy. Its therapeutic efficacy primarily stems from inhibiting the renin-angiotensin-aldosterone system (RAAS), making it a cornerstone in treating these cardiovascular conditions. Captopril effectively mitigates the pathophysiological cascades contributing to hypertension and heart failure by impeding the conversion of angiotensin I to angiotensin II. This activity sheds light on captopril's mechanism of action, dosage considerations, pharmacodynamics, and monitoring strategies. Additionally, captopril's off-label uses in acute hypertensive crises and the Raynaud phenomenon will be discussed, equipping clinicians and interprofessional team members with essential knowledge to administer captopril. Awareness of its adverse event profile and potential toxicities is crucial in ensuring captopril's safe and effective integration into clinical practice.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients with hypertension, heart failure, post-MI left ventricular dysfunction, or diabetic nephropathy who may benefit from captopril therapy.</p></list-item><list-item><p>Screen patients for contraindications, such as a history of angioedema or bilateral renal artery stenosis, before initiating captopril treatment.</p></list-item><list-item><p>Implement appropriate dosing strategies for captopril based on the patient's condition, renal function, and concurrent medications.</p></list-item><list-item><p>Apply knowledge of the potential adverse effects of captopril, including cough, hypotension, hyperkalemia, and renal dysfunction, to manage and minimize their impact on patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18835&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18835">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18835.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>
<bold>Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial therapy for patients with normal renal function.</p>
          </list-item>
          <list-item>
            <p>In patients with impaired renal function, captopril should be reserved for those patients who have developed unacceptable side effects or failed to respond to other drug therapy.<xref ref-type="bibr" rid="article-18835.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Effective alone and in combination with other antihypertensive agents.</p>
          </list-item>
        </list>
        <p>
<bold>Heart Failure</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>According to AHA/ACC/HFSA 2022 guidelines, captopril is indicated for managing HFrEF (heart failure with reduced ejection fraction). ACE inhibitors, including captopril,&#x000a0;are included in goal-directed medical therapy (GDMT), with an&#x000a0;established&#x000a0;reduced risk of rehospitalization and&#x000a0;improved survival.<xref ref-type="bibr" rid="article-18835.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Left Ventricular Dysfunction After Myocardial Infarction</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Captopril improves survival following myocardial infarction in clinically stable patients with a left ventricular ejection fraction of less than 40% and reduces the&#x000a0;incidence of hospitalization.<xref ref-type="bibr" rid="article-18835.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Captopril prevents remodeling and reduces cardiovascular mortality in patients with heart failure.</p>
          </list-item>
        </list>
        <p>
<bold>Diabetic Nephropathy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic nephropathy is the leading cause of end-stage kidney disease (ESKD) in developed countries.&#x000a0;This condition is due to&#x000a0;microvascular complications of diabetes and can occur in type 1 and type 2 diabetes. Early treatment can prevent or slow the onset of diabetic nephropathy.<xref ref-type="bibr" rid="article-18835.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Hyperglycemia leads to the production of reactive oxygen species. Producing advanced glycation end products (AGE) and cytokines (IL-6, MCP-1, TGF-&#x003b2;, VEGF) causes inflammation and fibrosis, leading to increased vascular permeability and albuminuria. Kimmelstiel-Wilson nodules, glomerular basement membrane thickening, and glomerular sclerosis are the pathological manifestations of diabetic nephropathy. The duration of diabetes, poor glycemic control, uncontrolled hypertension, obesity, smoking, and hyperlipidemia are major risk factors for developing diabetic nephropathy (DN).<xref ref-type="bibr" rid="article-18835.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Diabetic nephropathy&#x000a0;can be diagnosed by constant albuminuria on&#x000a0;2 or more occasions, separated by&#x000a0;3 months. Persistent albuminuria is &#x0003e;300 mg over 24 hours or &#x0003e;200&#x000a0;&#x003bc;g/min. Moderately increased albuminuria is defined as a urine albumin&#x000a0;of 30 to 300 mg over 24 hours and is a sign of early diabetic nephropathy. Other critical diagnostic criteria include elevated blood pressure, a decline in GFR, and persistent albuminuria (&#x0003e;300 mg/d) on at least&#x000a0;2 occasions 3&#x000a0;to 6 months apart.<xref ref-type="bibr" rid="article-18835.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of diabetic nephropathy (proteinuria &#x0003e;500 mg/d) in patients with type 1 insulin-dependent diabetes and retinopathy.&#x000a0;An angiotensin-converting enzyme (ACE) inhibitor, captopril, is FDA-approved to treat diabetic nephropathy. Enalapril is not FDA-approved to treat diabetic nephropathy.<xref ref-type="bibr" rid="article-18835.r3">[3]</xref>&#x000a0;Captopril decreases the rate of progression of renal insufficiency by controlling blood pressure.&#x000a0;With chronic renal failure, ACE inhibitors or ARBs must be dose-adjusted for patients with renal impairment.<xref ref-type="bibr" rid="article-18835.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment involves smoking cessation, good glycemic control, good blood pressure control (130/80 or&#x000a0;lower in patients with diabetes), and inhibition of the renin-angiotensin-aldosterone system with ARBs or ACE inhibitors. According to the ADA (American Diabetes&#x000a0;Association) and&#x000a0;KDIGO (Kidney Disease: Improving Global Outcomes) guidelines,&#x000a0;ACE inhibitors are&#x000a0;recommended for&#x000a0;patients with&#x000a0;diabetes, hypertension, and albumin-to-creatinine ratio (ACR) &#x0003e;300 mg/g as they prevent CKD progression. If ACR is 30&#x000a0;to 299 mg/g, treatment with an ACE inhibitor reduces cardiovascular events.&#x000a0;Consequently,&#x000a0;KDIGO and the ADA&#x000a0;suggest ACE inhibitor treatment for&#x000a0;patients with hypertension and diabetes with ACR &#x02265;30 mg/g.<xref ref-type="bibr" rid="article-18835.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>
<bold>Acute Hypertensive Crisis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Captopril may be&#x000a0;given sublingually, but the&#x000a0;therapeutic advantage has not been demonstrated over oral administration.<xref ref-type="bibr" rid="article-18835.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Consider alternative therapy if blood pressure does not normalize within 20 to 30 minutes.<xref ref-type="bibr" rid="article-18835.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Raynaud Phenomenon</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinically, the Raynaud phenomenon&#x000a0;is characterized by discoloration of the fingers due to stressors like cold or emotion. When this phenomenon occurs without any underlying condition, this is termed Raynaud disease. In contrast, Raynaud syndrome occurs due to an underlying condition. This disease most commonly affects females with an age of onset&#x000a0;younger than 30. Fingers are more commonly affected than toes. Some common risk factors include family history, history of autoimmune diseases, and exposure to beta-blockers.<xref ref-type="bibr" rid="article-18835.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>This condition occurs due to the vasospasm of blood vessels supplying&#x000a0;the skin, which causes impaired vasodilation and vasoconstriction. Most patients have all&#x000a0;3 phases with white (suggesting an ischemic process), blue (indicating hypoxia and cyanosis), and pink (indicating reperfusion) coloration, while some have only 1 or 2 of these phases. Patients can also present with ulcers and gangrene due to reduced perfusion.<xref ref-type="bibr" rid="article-18835.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>The Raynaud phenomenon&#x000a0;is diagnosed clinically, and a cold stimulation test can precipitate an attack. Labs are needed only if another condition is suspected. Treatment involves avoiding colds and smoking cessation. Medical management consists of dihydropyridine-type calcium channel blockers (eg, nifedipine or nimodipine) and phosphodiesterase inhibitors. Some studies have highlighted that captopril decreases the frequency and severity of ischemic attacks in patients with Raynaud disease but not in patients with scleroderma. However, more definitive studies are needed to elucidate its effects.<xref ref-type="bibr" rid="article-18835.r7">[7]</xref>&#x000a0;A clinical trial evaluated patients for up to&#x000a0;3 months; additional studies are&#x000a0;necessary to determine full effectiveness.<xref ref-type="bibr" rid="article-18835.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18835.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The benefits of captopril in hypertension and heart failure result primarily from suppressing the renin-angiotensin-aldosterone system (RAAS).<xref ref-type="bibr" rid="article-18835.r9">[9]</xref> An angiotensin-converting enzyme (ACE) inhibitor inhibits ACE, converting angiotensin I to angiotensin II. Angiotensin II binds to AT1 receptors on smooth muscles to produce vasoconstriction of precapillary arterioles and postcapillary venules, inhibiting norepinephrine reuptake and releasing catecholamines from the adrenal medulla, which all increase blood pressure. Angiotensin II also stimulates the adrenal cortex to secrete aldosterone. Aldosterone causes the distal tubules and collecting ducts of the kidneys to reabsorb water and sodium in exchange&#x000a0;for potassium, which results in an expansion in extracellular volume and an increase in blood pressure.<xref ref-type="bibr" rid="article-18835.r10">[10]</xref></p>
        <p>ACE inhibition leads to decreased plasma angiotensin II, resulting in vasodilation and reduced aldosterone secretion. Small increases in serum potassium and sodium and fluid loss may occur due to decreased aldosterone secretion.<xref ref-type="bibr" rid="article-18835.r1">[1]</xref>&#x000a0;</p>
        <p>Captopril results in a reduction of peripheral arterial resistance in hypertensive patients. Regarding the cardiovascular system, ACE inhibitors reduce preload by causing vasodilation and natriuresis and reduce afterload by inhibiting the formation of angiotensin II. The overall effect is the improvement of cardiac output and reduced blood pressure.<xref ref-type="bibr" rid="article-18835.r11">[11]</xref>&#x000a0;</p>
        <p>ACE also metabolizes bradykinin, a peptide that causes vasodilation. ACE inhibitors impede the breakdown of bradykinin, resulting in vasodilation and a bradykinin-evoked cough.&#x000a0;The only&#x000a0;2 ACE inhibitors that do not have to be activated in the body to be effective are lisinopril and captopril, while others require activation to&#x000a0;exert their effect.<xref ref-type="bibr" rid="article-18835.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Captopril is well-absorbed orally, with peak plasma concentration achieved within approximately&#x000a0;1 hour of administration. Food decreases the bioavailability of captopril; captopril should be administered&#x000a0;1 hour before meals.</p>
        <p><bold>Distribution:</bold> The volume of distribution is 0.8 L/kg. Plasma protein binding is approximately 25% to 30%. Captopril can cross the blood-brain barrier.<xref ref-type="bibr" rid="article-18835.r12">[12]</xref></p>
        <p><bold>Metabolism:</bold> Captopril is metabolized to cysteine-captopril disulfide and captopril dimer disulfide.<xref ref-type="bibr" rid="article-18835.r13">[13]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;The kidney is the major&#x000a0;route of elimination of captopril. The clearance is 0.7 L/h/kg, and the elimination half-life is approximately 2 hours; thrice daily administration is required. The clearance of captopril (unchanged) is greater than the glomerular filtration rate due&#x000a0;to the active tubular secretion.<xref ref-type="bibr" rid="article-18835.r14">[14]</xref></p>
      </sec>
      <sec id="article-18835.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Captopril should be taken 1 hour before meals. Therapy initiation requires analysis of recent antihypertensive drug treatment, the extent of blood pressure elevation, and salt restriction.&#x000a0;If possible, the previous antihypertensive drug regimen should be stopped&#x000a0;1 week before starting captopril. The daily&#x000a0;dose of captopril may be increased every 24 hours under continuous medical supervision. The initial daily dosage should be reduced for patients with significant renal impairment, and smaller increments should be utilized for titration.&#x000a0;</p>
        <p>
<bold>Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial dosage: 25 mg, 2 times&#x000a0;or 3 times per day</p>
          </list-item>
          <list-item>
            <p>Unsatisfactory reduction of blood pressure after&#x000a0;1 to 2&#x000a0;weeks: Increase the dosage to 50 mg, 2 or 3&#x000a0;times daily.</p>
          </list-item>
          <list-item>
            <p>The dosage of captopril may increase to 100 mg, 2&#x000a0;or 3 times daily, and to 150 mg, 2 or 3 times daily, if&#x000a0;further blood pressure reduction is required.</p>
          </list-item>
          <list-item>
            <p>The usual dosage range is 25 to 150 mg, 2 or 3 times daily. The maximum daily dose&#x000a0;should not exceed&#x000a0;450 mg.<xref ref-type="bibr" rid="article-18835.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Heart Failure</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The initial dosage&#x000a0;in patients vigorously treated with diuretics,&#x000a0;hyponatremic, and&#x000a0;hypovolemic patients is 6.25 or 12.5 mg, 3 times daily with titration to the usual daily dosage within several days.</p>
          </list-item>
          <list-item>
            <p>According to AHA/ACC/HFSA guidelines, the initial dosage in patients is 6.25 mg, 3 times daily, and the target dosage is 50&#x000a0;mg, 3 times daily.<xref ref-type="bibr" rid="article-18835.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>After a dosage of 50 mg, 3 times daily, further increases in dosage should be delayed for at least&#x000a0;2 weeks.<xref ref-type="bibr" rid="article-18835.r16">[16]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Left Ventricular Dysfunction after Myocardial Infarction</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>After a single dose of 6.25 mg, captopril therapy should be initiated at 12.5 mg, 3 times daily, and then increased to 25 mg, 3 times daily, over several days.</p>
          </list-item>
          <list-item>
            <p>Long-term use: target maintenance dose of 50 mg, 3 times daily.</p>
          </list-item>
          <list-item>
            <p>Therapy can be initiated as early as&#x000a0;3 days following myocardial infarction.<xref ref-type="bibr" rid="article-18835.r17">[17]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Diabetic Nephropathy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Long-term use: 25 mg, 3 times daily&#x000a0;<xref ref-type="bibr" rid="article-18835.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Acute Hypertensive Crisis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dosed orally or sublingually: 25 mg. Alternative therapy should be considered if blood pressure is nonresponsive within 20 to 30 minutes.<xref ref-type="bibr" rid="article-18835.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Raynaud Phenomenon</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The initial dosage is 12.5 mg, 2 times&#x000a0;daily; it can gradually increase to 25 mg, 3 times daily.<xref ref-type="bibr" rid="article-18835.r8">[8]</xref>&#x000a0;The starting dosage may gradually increase to 25 mg,&#x000a0;3 times daily.</p>
          </list-item>
          <list-item>
            <p>Neutropenia is a common adverse event with captopril administration in patients with the Raynaud phenomenon.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>No information is provided in the manufacturer's labeling.&#x000a0;According to AASLD (American Association for the Study of Liver Diseases), ACE inhibitors should be avoided in patients with cirrhosis and ascites.<xref ref-type="bibr" rid="article-18835.r19">[19]</xref></p>
        <p><bold>Renal impairment:</bold>&#x000a0;As discussed in pharmacokinetics, captopril is primarily excreted by the kidney. The initial dose of captopril should be decreased for significant renal impairment, and&#x000a0;gradual up-titration is advised.</p>
        <p><bold>Pregnancy considerations: </bold>Captopril is FDA pregnancy category D.&#x000a0;Drug use that acts on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.&#x000a0;Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.<xref ref-type="bibr" rid="article-18835.r20">[20]</xref>&#x000a0;Captopril must be discontinued as soon as possible when pregnancy is confirmed.</p>
        <p><bold>Breastfeeding considerations: </bold>Captopril is present in breast milk at approximately 1% of those in maternal blood.&#x000a0;Captopril may be considered acceptable for use in&#x000a0;breastfeeding.&#x000a0;Monitor the weight of the breastfeeding child for the first&#x000a0;4 weeks.&#x000a0;However, the manufacturer recommends discontinuing breastfeeding or captopril due to the possibility of severe adverse reactions in nursing infants. A risk-benefit analysis should consider the importance of captopril therapy for the mother.<xref ref-type="bibr" rid="article-18835.r21">[21]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>According to AAP (American Academy of Pediatrics) guidelines, the recommended initial dose for infants is&#x000a0;0.05 mg/kg 4 times daily, and the maximum recommended dose is&#x000a0;6 mg/kg/d. The initial dose is&#x000a0;0.5 mg/kg&#x000a0;3 times daily for children, and the maximum recommended dose is 6 mg/kg/d.<xref ref-type="bibr" rid="article-18835.r22">[22]</xref></p>
        <p><bold>Older patients:&#x000a0;</bold>Consider the comprehensive evaluation of comorbidities, including renal impairment and polypharmacy; monotherapy is recommended at a low dose in frail patients.<xref ref-type="bibr" rid="article-18835.r23">[23]</xref></p>
      </sec>
      <sec id="article-18835.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>While captopril is generally well-tolerated, it does have several potential adverse effects.<xref ref-type="bibr" rid="article-18835.r24">[24]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Dry&#x000a0;cough (1% to 10%)&#x000a0;<xref ref-type="bibr" rid="article-18835.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Proteinuria (1%), which subsides or clears within&#x000a0;6 months even when captopril therapy is continued&#x000a0;<xref ref-type="bibr" rid="article-18835.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Renal insufficiency, renal failure, nephrotic syndrome, polyuria, oliguria, and urinary frequency (0.1% to 0.2%)&#x000a0;<xref ref-type="bibr" rid="article-18835.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Neutropenia (&#x0003c;1000/mm<sup>3</sup>) or agranulocytosis with myeloid hypoplasia</p>
          </list-item>
          <list-item>
            <p>Rash with pruritus and occasionally with fever, arthralgia, and eosinophilia (4% to 7%)&#x000a0;<xref ref-type="bibr" rid="article-18835.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Angina pectoris, myocardial infarction, Raynaud syndrome, and congestive heart failure (0.2% to 0.3%)&#x000a0;<xref ref-type="bibr" rid="article-18835.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Dysgeusia (diminution or loss of taste perception) is reversible and usually self-limited (2% to 4%) <xref ref-type="bibr" rid="article-18835.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Anaphylactoid and other related reactions due to the inhibition of the metabolism of eicosanoids and polypeptides, including bradykinin</p>
          </list-item>
          <list-item>
            <p>Angioedema can occur in any region, such as the intestine, but angioedema of the tongue, glottis, or larynx causes airway obstruction. The prevalence of angioedema is higher in the African-American population. Treatment for angioedema involving the airways involves immediate stabilization with an endotracheal tube until the swelling resolves. Many pharmacological agents like diphenhydramine, methylprednisolone, epinephrine, or bradykinin blocking agents have been tried as treatment without a definitive answer&#x000a0;<xref ref-type="bibr" rid="article-18835.r11">[11]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Intestinal angioedema, which presents as abdominal pain with or without nausea or vomiting&#x000a0;<xref ref-type="bibr" rid="article-18835.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Flushing or pallor&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Tachycardia, chest pain, and palpitations</p>
          </list-item>
          <list-item>
            <p>Hypotension&#x000a0;<xref ref-type="bibr" rid="article-18835.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>ACE inhibitors may cause hyperkalemia. Individuals more prone to developing hyperkalemia have a history of renal impairment or diabetes, concurrent use of potassium-sparing diuretics, or potassium&#x000a0;supplements. Treatment planning should also&#x000a0;consider factors such as potassium levels, EKG changes, and the patient&#x02019;s renal function and urine production.<xref ref-type="bibr" rid="article-18835.r11">[11]</xref>&#x000a0;There has been&#x000a0;1 case of sudden death in a patient taking an ACE inhibitor and trimoxazole simultaneously. Hyperkalemia was assumed to be the cause since it can trigger lethal arrhythmias.<xref ref-type="bibr" rid="article-18835.r11">[11]</xref>&#x000a0;Symptoms of hyperkalemia can range from nausea, palpitations, muscle pain, or paresthesia. Electrocardiography (ECG) monitoring is required in patients with serum potassium &#x0003e;6.5&#x000a0;mmol/L. ECG changes may present as non-specific repolarization abnormalities, peaked T-waves, widening of QRS, and ST-segment depression.&#x000a0;Treatment involves immediate stabilization of cardiac myocytes with calcium gluconate, dextrose, and insulin infusion or beta-agonists. The last step involves removing total body potassium using loop diuretics, polystyrene sulfonate, or hemodialysis.<xref ref-type="bibr" rid="article-18835.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Precautions</bold>
</p>
        <p><bold>Hypertension:</bold> Increased&#x000a0;BUN&#x000a0;and serum creatinine have been observed in some patients with renal disease.<xref ref-type="bibr" rid="article-18835.r20">[20]</xref></p>
        <p><bold>Heart failure:</bold> Elevations of BUN and serum creatinine greater than 20% above normal or baseline with long-term treatment&#x000a0;<xref ref-type="bibr" rid="article-18835.r16">[16]</xref></p>
        <p><bold>Hyperkalemia:</bold> Elevations in serum potassium</p>
        <p><bold>Surgery/Anesthesia:</bold> In patients undergoing major surgery with anesthesia with agents that produce hypotension, captopril will block angiotensin II formation, and hypotension may result.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>Aliskiren:</bold> Captopril should not be coadministered with aliskiren in patients with diabetes.<xref ref-type="bibr" rid="article-18835.r3">[3]</xref></p>
        <p><bold>Angiotensin-II receptor blockers:</bold> Dual therapy blockade of the&#x000a0;renin-angiotensin-aldosterone system&#x000a0;(RAAS) with ARBs and ACE inhibitors increases the risk of renal failure and hyperkalemia. The combination is not recommended.<xref ref-type="bibr" rid="article-18835.r28">[28]</xref></p>
        <p><bold>NSAIDS:</bold>&#x000a0;The antihypertensive effect of captopril is decreased&#x000a0;by NSAIDs. NSAIDS can also cause worsening&#x000a0;renal function and potential acute&#x000a0;kidney&#x000a0;injury.<xref ref-type="bibr" rid="article-18835.r29">[29]</xref></p>
        <p><bold>Diuretics:</bold> Diuretics increase the risk of hypotension and acute kidney injury when administered concomitantly with captopril. Optimize and monitor volume status before initiating therapy.<xref ref-type="bibr" rid="article-18835.r24">[24]</xref></p>
        <p><bold>Lithium:</bold> Concomitant therapy with lithium and ACE inhibitors increases serum lithium&#x000a0;concentration&#x000a0;and the risk of lithium toxicity.<xref ref-type="bibr" rid="article-18835.r30">[30]</xref></p>
        <p><bold>Digoxin:</bold>&#x000a0;Concomitant&#x000a0;use of captopril with digoxin increases serum digoxin&#x000a0;levels,&#x000a0;especially in severe congestive heart failure. Use with caution.<xref ref-type="bibr" rid="article-18835.r31">[31]</xref></p>
        <p><bold>Drug-Laboratory&#x000a0;interaction:</bold> Captopril may cause&#x000a0;a false-positive urine test for acetone in patients with diabetes.<xref ref-type="bibr" rid="article-18835.r32">[32]</xref></p>
      </sec>
      <sec id="article-18835.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to captopril use include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity to captopril, any component of the formulation, or any other ACEI</p>
          </list-item>
          <list-item>
            <p>Angioedema&#x000a0;related to previous treatment with ACEI</p>
          </list-item>
          <list-item>
            <p>Concomitant aliskiren use in patients with diabetes <xref ref-type="bibr" rid="article-18835.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Coadministration with or within 36 hours of switching to or from a neprilysin inhibitor (sacubitril)&#x000a0;<xref ref-type="bibr" rid="article-18835.r33">[33]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Boxed Warning</bold>
</p>
        <p>Captopril&#x000a0;has a boxed warning of fetal toxicity. Exposure of the fetus to ACE inhibitors in pregnancy has adverse pregnancy outcomes that can lead to fetal lung hypoplasia, skull hypoplasia, renal agenesis, and oligohydramnios. ACE inhibitors are associated with congenital malformations and miscarriages. If pregnancy is detected, clinicians should discontinue captopril immediately.<xref ref-type="bibr" rid="article-18835.r34">[34]</xref><xref ref-type="bibr" rid="article-18835.r35">[35]</xref></p>
      </sec>
      <sec id="article-18835.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The patient's BUN, electrolytes, serum creatinine, and blood pressure require routine monitoring.&#x000a0;If captopril&#x000a0;is initiated&#x000a0;in patients with impaired renal function or collagen vascular disease,&#x000a0;the complete blood count with differential (risk of agranulocytosis) should be evaluated before starting treatment and at 2-week intervals for about&#x000a0;3 months, then periodically after that.<xref ref-type="bibr" rid="article-18835.r20">[20]</xref></p>
        <p>All patients treated with captopril receive counsel to report any signs of infection, including sore throat or fever. Patients with heart failure should be followed closely for the first&#x000a0;2 weeks of treatment and whenever the dose of captopril is titrated, especially in patients with preexisting hypotension, hyponatremia, diabetes, azotemia, or those taking potassium supplements due to the potential for excessive hypotension, arrhythmia, and conduction defects.<xref ref-type="bibr" rid="article-18835.r36">[36]</xref>&#x000a0;</p>
        <p>According to the latest hypertension guidelines, patients with or without CVD or increased ASVD risk&#x000a0;should maintain a blood pressure lower than 130/80 mm Hg while on therapy. On the other hand, according to the diabetes guidelines, adult patients with both diabetes and hypertension have a goal blood pressure of&#x000a0;lower than 140/90 mm Hg.<xref ref-type="bibr" rid="article-18835.r37">[37]</xref></p>
        <p>Renal function in patients&#x000a0;being administered captopril and NSAID therapy should be monitored. Additionally, lithium levels should be monitored in patients taking this medication.<xref ref-type="bibr" rid="article-18835.r30">[30]</xref></p>
      </sec>
      <sec id="article-18835.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Correction of hypotension is the primary concern through volume expansion with an intravenous infusion of normal saline. Excessive hypotension has been rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume-depleted persons. ACE inhibitors have rarely shown an association with a syndrome that begins with cholestatic jaundice and progresses to fulminant hepatic necrosis and sometimes death.<xref ref-type="bibr" rid="article-18835.r1">[1]</xref>&#x000a0;</p>
        <p>Captopril should be discontinued if a marked elevation of hepatic transaminases or jaundice occurs. A persistent, dry, hacking, nonproductive cough within the first few months of treatment can also occur with captopril therapy. ACE inhibitor-induced cough results from inhibiting the degradation of bradykinin and generally&#x000a0;resolves within 1 to 4 weeks after discontinuation.</p>
        <p>Acute captopril overdose presents with profound hypotension, acute&#x000a0;kidney&#x000a0;injury, central hypoperfusion, and altered mental status. Management is&#x000a0;primarily supportive. Maintenance of hemodynamics with IV fluids and vasopressors is required. The literature review suggests the role of dialysis in acute overdose.<xref ref-type="bibr" rid="article-18835.r38">[38]</xref>&#x000a0;Case reports also describe the role of naloxone in the reversal of ACE inhibitor toxicity, including captopril.<xref ref-type="bibr" rid="article-18835.r39">[39]</xref>&#x000a0;The proposed mechanism is the impact of ACE inhibitors on the endogenous opioid systems, leading to the accumulation of enkephalin and its reversal by naloxone.<xref ref-type="bibr" rid="article-18835.r40">[40]</xref></p>
      </sec>
      <sec id="article-18835.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Captopril is a widely prescribed drug in clinical medicine. Physicians&#x000a0;and advanced practice practitioners who prescribe this medication for hypertension should be aware of its side effects and the need to monitor electrolytes and renal function. Cardiologist consultation is required for managing HFrEF, post-MI LV dysfunction, and optimization of GDMT.&#x000a0;Nephrology consultation can provide&#x000a0;evidence-based strategies for&#x000a0;the management of diabetic neuropathy. Emergency medicine and critical care physicians play an essential&#x000a0;role in overdose. Medical toxicologists offer valuable information regarding the latest treatment for overdose.&#x000a0;</p>
        <p>Nurses can provide patient counseling, assess compliance, and coordinate with the prescriber if they note any changes in patient status, including therapeutic failure or adverse events. The pharmacist should keep track of the patient's medications to&#x000a0;help reduce polypharmacy and drug interactions and&#x000a0;educate the patient about adverse reactions that they should monitor,&#x000a0;instructing them to contact&#x000a0;their care team promptly should any arise. Nurses and pharmacists should immediately consult with the prescriber to alert them to any concerns regarding the patient's regimen and progress or lack thereof.</p>
        <p>An interprofessional approach and open communication between all healthcare team members, including clinicians, specialists, pharmacists, and medical toxicologists, can minimize adverse drug reactions and improve the outcomes related to&#x000a0;captopril therapy.&#x000a0;</p>
      </sec>
      <sec id="article-18835.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18835&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18835">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18835/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18835">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18835.s11">
        <title>References</title>
        <ref id="article-18835.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Nov</month>
            <day>14</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>CD008170</fpage>
            <pub-id pub-id-type="pmid">30480768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>79</volume>
            <issue>17</issue>
            <fpage>e263</fpage>
            <page-range>e263-e421</page-range>
            <pub-id pub-id-type="pmid">35379503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Varghese</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Diabetic Nephropathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">30480939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Boer</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sadusky</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tuttle</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Neumiller</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Rosas</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Rossing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).</article-title>
            <source>Diabetes Care</source>
            <year>2022</year>
            <month>Dec</month>
            <day>01</day>
            <volume>45</volume>
            <issue>12</issue>
            <fpage>3075</fpage>
            <page-range>3075-3090</page-range>
            <pub-id pub-id-type="pmid">36189689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karakili&#x000e7;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>B&#x000fc;y&#x000fc;kcam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kocalar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gedik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Atalar</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Same effect of sublingual and oral captopril in hypertensive crisis.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>1642</fpage>
            <page-range>1642-5</page-range>
            <pub-id pub-id-type="pmid">23161035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damasceno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sevene</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pol&#x000f3;nia</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of captopril and nifedipine in black and white patients with hypertensive crisis.</article-title>
            <source>J Hum Hypertens</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>471</fpage>
            <page-range>471-6</page-range>
            <pub-id pub-id-type="pmid">9322826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Musa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Qurie</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Raynaud Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">29763008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tosi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marchesoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bellintani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sironi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Faravelli</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Raynaud's phenomenon with captopril.</article-title>
            <source>Drugs Exp Clin Res</source>
            <year>1987</year>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-42</page-range>
            <pub-id pub-id-type="pmid">3297593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Captopril alleviates hypertension-induced renal damage, inflammation, and NF-&#x003ba;B activation.</article-title>
            <source>Braz J Med Biol Res</source>
            <year>2018</year>
            <month>Sep</month>
            <day>03</day>
            <volume>51</volume>
            <issue>11</issue>
            <fpage>e7338</fpage>
            <pub-id pub-id-type="pmid">30183974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lezama-Martinez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Flores-Monroy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fonseca-Coronado</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hernandez-Campos</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Valencia-Hernandez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Martinez-Aguilar</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Combined Antihypertensive Therapies That Increase Expression of Cardioprotective Biomarkers Associated With the Renin-Angiotensin and Kallikrein-Kinin Systems.</article-title>
            <source>J Cardiovasc Pharmacol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>6</issue>
            <fpage>291</fpage>
            <page-range>291-295</page-range>
            <pub-id pub-id-type="pmid">30422889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Herman</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Padala</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Angiotensin-Converting Enzyme Inhibitors (ACEI)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">28613705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Moriarty</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manly</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Rajan</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Hudak</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hasebe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Laurin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carmichael</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Nation</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis.</article-title>
            <source>Hypertension</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>629</fpage>
            <page-range>629-643</page-range>
            <pub-id pub-id-type="pmid">34148364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zisaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miskovic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hatzimanikatis</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.</article-title>
            <source>Curr Pharm Des</source>
            <year>2015</year>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>806</fpage>
            <page-range>806-22</page-range>
            <pub-id pub-id-type="pmid">25341854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duchin</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>McKinstry</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Migdalof</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1988</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>241</fpage>
            <page-range>241-59</page-range>
            <pub-id pub-id-type="pmid">3292102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <article-title>Treating essential hypertension. The first choice is usually a thiazide diuretic.</article-title>
            <source>Prescrire Int</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>152</issue>
            <fpage>215</fpage>
            <page-range>215-20</page-range>
            <pub-id pub-id-type="pmid">25325125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ogawa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stachnik</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Echizen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>53</volume>
            <issue>12</issue>
            <fpage>1083</fpage>
            <page-range>1083-114</page-range>
            <pub-id pub-id-type="pmid">25248847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Leo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Panarese</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gallerani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ceci</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin converting enzyme (ACE) inhibitory peptides: production and implementation of functional food.</article-title>
            <source>Curr Pharm Des</source>
            <year>2009</year>
            <volume>15</volume>
            <issue>31</issue>
            <fpage>3622</fpage>
            <page-range>3622-43</page-range>
            <pub-id pub-id-type="pmid">19925416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adeghate</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kalasz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Veress</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Teke</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Medicinal chemistry of drugs used in diabetic cardiomyopathy.</article-title>
            <source>Curr Med Chem</source>
            <year>2010</year>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>517</fpage>
            <page-range>517-51</page-range>
            <pub-id pub-id-type="pmid">20015035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biggins</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Angeli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Garcia-Tsao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gin&#x000e8;s</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Nadim</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.</article-title>
            <source>Hepatology</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>74</volume>
            <issue>2</issue>
            <fpage>1014</fpage>
            <page-range>1014-1048</page-range>
            <pub-id pub-id-type="pmid">33942342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindle</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Dinh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moffett</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Denfield</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Knudson</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease.</article-title>
            <source>Pediatr Cardiol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>499</fpage>
            <page-range>499-506</page-range>
            <pub-id pub-id-type="pmid">24233240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regitz-Zagrosek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Roos-Hesselink</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blomstr&#x000f6;m-Lundqvist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>C&#x000ed;fkov&#x000e1;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Bonis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kintscher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kranke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Morais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Presbitero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Seeland</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Simoncini</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Warnes</surname>
                <given-names>CA</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</article-title>
            <source>Eur Heart J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>07</day>
            <volume>39</volume>
            <issue>34</issue>
            <fpage>3165</fpage>
            <page-range>3165-3241</page-range>
            <pub-id pub-id-type="pmid">30165544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flynn</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Kaelber</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Baker-Smith</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Blowey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Dionne</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Falkner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leu</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Rea</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Simasek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thaker</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Urbina</surname>
                <given-names>EM</given-names>
              </name>
              <collab>SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN</collab>
            </person-group>
            <article-title>Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.</article-title>
            <source>Pediatrics</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>140</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">28827377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Charchar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Prabhakaran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schlaich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stergiou</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wainford</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schutte</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>2020 International Society of Hypertension Global Hypertension Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>1334</fpage>
            <page-range>1334-1357</page-range>
            <pub-id pub-id-type="pmid">32370572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prieto-Garc&#x000ed;a</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pericacho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sancho-Mart&#x000ed;nez</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Salgado</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Novoa</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Hern&#x000e1;ndez</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of triple whammy acute kidney injury.</article-title>
            <source>Pharmacol Ther</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>167</volume>
            <fpage>132</fpage>
            <page-range>132-145</page-range>
            <pub-id pub-id-type="pmid">27490717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e1;nchez-Borges</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Aveledo</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitors and angioedema.</article-title>
            <source>Allergy Asthma Immunol Res</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-8</page-range>
            <pub-id pub-id-type="pmid">20592919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antunes</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Guerrante</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>&#x000c1;vila</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lins Mendes</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Fierro</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Case study of patents related to captopril, Squibb's first blockbuster.</article-title>
            <source>Expert Opin Ther Pat</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>1449</fpage>
            <page-range>1449-1457</page-range>
            <pub-id pub-id-type="pmid">27573807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lehnhardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kemper</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis, diagnosis and management of hyperkalemia.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>377</fpage>
            <page-range>377-84</page-range>
            <pub-id pub-id-type="pmid">21181208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fried</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Emanuele</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Brophy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Conner</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Duckworth</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Leehey</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>McCullough</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Palevsky</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Seliger</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Watnick</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peduzzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guarino</surname>
                <given-names>P</given-names>
              </name>
              <collab>VA NEPHRON-D Investigators</collab>
            </person-group>
            <article-title>Combined angiotensin inhibition for the treatment of diabetic nephropathy.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Nov</month>
            <day>14</day>
            <volume>369</volume>
            <issue>20</issue>
            <fpage>1892</fpage>
            <page-range>1892-903</page-range>
            <pub-id pub-id-type="pmid">24206457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tominey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Timmins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Lone</surname>
                <given-names>NI</given-names>
              </name>
            </person-group>
            <article-title>Community prescribing of potentially nephrotoxic drugs and risk of acute kidney injury requiring renal replacement therapy in critically ill adults: A national cohort study.</article-title>
            <source>J Intensive Care Soc</source>
            <year>2021</year>
            <month>May</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-110</page-range>
            <pub-id pub-id-type="pmid">34025749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Juurlink</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Mamdani</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rochon</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Shulman</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Redelmeier</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced lithium toxicity in the elderly: a population-based study.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2004</year>
            <month>May</month>
            <volume>52</volume>
            <issue>5</issue>
            <fpage>794</fpage>
            <page-range>794-8</page-range>
            <pub-id pub-id-type="pmid">15086664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirimli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kalkan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guneri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tuncok</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Akdeniz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ozdamar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guven</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The effects of captopril on serum digoxin levels in patients with severe congestive heart failure.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>39</volume>
            <issue>7</issue>
            <fpage>311</fpage>
            <page-range>311-4</page-range>
            <pub-id pub-id-type="pmid">11471775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graham</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Naidoo</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>False-positive ketostix in a diabetic on antihypertensive therapy.</article-title>
            <source>Clin Chem</source>
            <year>1987</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>1490</fpage>
            <pub-id pub-id-type="pmid">3301073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Owens</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Oliphant</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results.</article-title>
            <source>J Am Board Fam Med</source>
            <year>2017</year>
            <season>Jul-Aug</season>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>556</fpage>
            <page-range>556-557</page-range>
            <pub-id pub-id-type="pmid">28720639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Levitt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Amsalem</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Reversible Fetal Renal Impairment following Angiotensin Receptor Blocking Treatment during Third Trimester of Pregnancy: Case Report and Review of the Literature.</article-title>
            <source>Case Rep Obstet Gynecol</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>2382031</fpage>
            <pub-id pub-id-type="pmid">27672462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shrim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kingdom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hamoudi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prolonged exposure to angiotensin-converting enzyme inhibitors during pregnancy. Fetal toxicity could be reversible.</article-title>
            <source>Can Fam Physician</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>10</issue>
            <fpage>1335</fpage>
            <page-range>1335-7</page-range>
            <pub-id pub-id-type="pmid">16250418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ong</surname>
                <given-names>HT</given-names>
              </name>
            </person-group>
            <article-title>Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?</article-title>
            <source>J Am Board Fam Med</source>
            <year>2009</year>
            <season>Nov-Dec</season>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>686</fpage>
            <page-range>686-97</page-range>
            <pub-id pub-id-type="pmid">19897698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>A Comparison of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline and the 2017 American Diabetes Association Diabetes and Hypertension Position Statement for U.S. Adults With Diabetes.</article-title>
            <source>Diabetes Care</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>2322</fpage>
            <page-range>2322-2329</page-range>
            <pub-id pub-id-type="pmid">30150235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Christie</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Waring</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Rapid onset of haemodynamic effects after angiotensin converting enzyme-inhibitor overdose: implications for initial patient triage.</article-title>
            <source>Emerg Med J</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>854</fpage>
            <page-range>854-7</page-range>
            <pub-id pub-id-type="pmid">17057137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Naloxone reversal of hypotension due to captopril overdose.</article-title>
            <source>Ann Emerg Med</source>
            <year>1991</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1125</fpage>
            <page-range>1125-7</page-range>
            <pub-id pub-id-type="pmid">1928887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18835.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trivedi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Glezerson</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Chaudhuri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doufl&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Naloxone as an antidote for angiotensin converting enzyme inhibitor poisoning: a case report.</article-title>
            <source>Can J Anaesth</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>67</volume>
            <issue>10</issue>
            <fpage>1442</fpage>
            <page-range>1442-1443</page-range>
            <pub-id pub-id-type="pmid">32342351</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
